GlassScriptPhysician profile
Ashley Rose Waldrep
NPI 1508394149
$3,054.69
in general payments reported to CMS, 2019-2025
38 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.57 · 2022: $156 · 2023: $94.06 · 2024: $1,700 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494 · Travel and Lodging: $1,282 · Education: $71.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.09 |
| Travel and Lodging | $1,281.97 |
| Education | $71.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $1,441.97 | 2024 | |
| Seagen INC. | $179.28 | 2021-2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $158.83 | 2025 | |
| Abbvie INC. | $116.63 | 2024-2025 | |
| Kite Pharma, INC. | $94.84 | 2025 | Yescarta |
| Daiichi Sankyo INC. | $76.37 | 2024-2025 | Enhertu, Vanflyta |
| Genentech USA, INC. | $75.40 | 2024-2025 | Tecentriq, Venclexta, Columvi |
| Merck Sharp & Dohme LLC | $72.30 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech, INC. | $53.45 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $49.12 | 2022-2023 | Epkinly, Imbruvica |
| Astellas Pharma US INC | $49.07 | 2024-2025 | Vyloy |
| Emd Serono, INC. | $48.99 | 2025 | |
| Servier Pharmaceuticals LLC | $43.14 | 2025 | |
| Array Biopharma INC | $41.06 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Genzyme Corporation | $39.02 | 2021-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $35.55 | 2024-2025 | Fruzaqla, Iclusig |
| Aveo Pharmaceuticals, INC. | $35.34 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.77 | 2025 | Imfinzi, Tagrisso |
| Incyte Corporation | $33.72 | 2024-2025 | Jakafi, Zynyz, Monjuvi |
| Caris Mpi, INC. | $32.82 | 2025 | Mi Cancer Seek |
| Glaxosmithkline, LLC. | $32.54 | 2025 | Jemperli, Zejula, Blenrep |
| Genmab U.S., INC. | $25.85 | 2025 | Epkinly |
| Janssen Scientific Affairs, LLC | $24.18 | 2021-2023 | Darzalex |
| Tersera Therapeutics LLC | $23.99 | 2025 | Zoladex |
| Janssen Biotech, INC. | $23.15 | 2025 | Rybrevant |
| Exelixis INC. | $20.38 | 2025 | Cabometyx |
| Eisai INC. | $19.16 | 2025 | |
| Rigel Pharmaceuticals, INC. | $18.84 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Jazz Pharmaceuticals INC. | $18.26 | 2025 | |
| Pfizer INC. | $17.75 | 2024 | |
| Pharmaessentia USA Corporation | $16.89 | 2025 | Besremi |
| E.R. Squibb & Sons, L.L.C. | $16.80 | 2024 | Opdualag |
| Geron Corporation | $15.53 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $15.28 | 2025 | Orserdu |
| Lilly USA, LLC | $14.17 | 2024 | Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $14.14 | 2024 | Xpovio |
| Syndax Pharmaceuticals, INC. | $13.88 | 2025 | |
| Alexion Pharmaceuticals, INC. | $13.23 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Waldrep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.